High Creatinine — Symptoms, Causes & Treatment | MyMedicPlus

Creatinine is a waste product from normal muscle metabolism, filtered exclusively by the kidneys. Elevated serum creatinine (hypercreatininemia) indicates impaired kidney function — the kidneys are failing to filter and excrete creatinine adequately. Normal serum creatinine is approximately 60–110 µmol/L (0.7–1.2 mg/dL) in men and 45–90 µmol/L (0.5–1.0 mg/dL) in women; values vary with muscle mass. An elevated creatinine is a key marker of reduced glomerular filtration rate (GFR) and is used with eGFR formula to stage chronic kidney disease (CKD) and guide management. Creatinine alone can underestimate kidney dysfunction in elderly patients and those with low muscle mass or malnutrition — the estimated GFR (eGFR), calculated using the CKD-EPI equation incorporating age, sex, and creatinine, provides a more accurate and clinically meaningful assessment of kidney filtering capacity. A single creatinine value must always be interpreted in the context of prior results — a rising trend is more clinically significant than any single absolute value, and a sudden rise of 26 µmol/L or more within 48 hours meets the diagnostic threshold for acute kidney injury (AKI).

Renal causes (most significant): chronic kidney disease from diabetic nephropathy (leading cause globally), hypertensive nephropathy, glomerulonephritis, polycystic kidney disease, and lupus nephritis. Pre-renal causes: dehydration, heart failure, and liver failure reducing renal perfusion. Post-renal causes: urinary tract obstruction (kidney stones, prostate enlargement, tumors) impairing urine drainage. Non-renal causes of mildly elevated creatinine: high-protein diet, intense exercise (increased creatinine production), large muscle mass, rhabdomyolysis (muscle breakdown), and certain medications (ACE inhibitors — benign hemodynamic effect, trimethoprim, cimetidine — blocking creatinine secretion). Contrast-induced nephropathy — an acute rise in creatinine following iodinated contrast media used in CT scanning — is a clinically important iatrogenic cause, particularly in patients with pre-existing CKD, diabetes, or intravascular volume depletion; risk is substantially reduced by pre-procedural intravenous hydration and use of iso-osmolar contrast agents.

Mildly elevated creatinine is typically asymptomatic and identified on routine blood tests. Significant kidney dysfunction causes: fatigue, reduced urine output (or increased nocturia in early CKD), ankle and facial swelling (fluid retention), loss of appetite, nausea, metallic taste, hypertension, pallor (renal anemia from reduced erythropoietin production), bone pain (renal osteodystrophy), and muscle cramps. Advanced uraemia (end-stage kidney disease) causes cognitive impairment, pericarditis, pruritus, and uraemic frost — a medical emergency requiring dialysis. Uraemic fetor — a characteristic ammonia-like odour on the breath from exhaled urea breakdown products — is a sign of severe uraemia. Hypertension develops in most CKD patients from sodium and water retention combined with activation of the renin-angiotensin-aldosterone system, further accelerating cardiovascular disease and kidney damage in a compounding cycle that represents the leading cause of death in this population.

Serum creatinine is used to calculate estimated GFR (eGFR) using the CKD-EPI equation. CKD staging: G1 (eGFR above 90, with kidney damage markers), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), G5 (below 15 — kidney failure). Urine protein-to-creatinine ratio (uACR) or 24-hour urine protein quantifies proteinuria, a key CKD progression marker. Renal ultrasound assesses kidney size (small kidneys suggest chronic damage), obstruction, cysts, and blood flow. Blood tests include electrolytes, bicarbonate, full blood count (anemia), PTH and calcium-phosphate (mineral metabolism), and iron studies. Renal biopsy is indicated when glomerulonephritis or rapidly progressive renal disease is suspected. Serial creatinine measurements over time are essential to identify acute-on-chronic kidney disease, where an acute superimposed insult causes disproportionate creatinine rise on a background of chronically elevated values.

Treat the underlying cause: optimize diabetes control (target HbA1c below 53 mmol/mol), control hypertension (target blood pressure 120–130/80 mmHg or below 120 if proteinuric), and treat glomerulonephritis with immunosuppression as appropriate. ACE inhibitors or ARBs reduce intraglomerular pressure and proteinuria — they are the cornerstone of kidney protection in diabetic and proteinuric CKD, even if initial creatinine rise of 15–20% occurs (acceptable and stabilizes). SGLT2 inhibitors (dapagliflozin, empagliflozin) provide additional cardiorenal protection in CKD with or without diabetes. Dietary protein restriction (0.6–0.8 g/kg/day) reduces uraemic load. Renal replacement therapy (dialysis or transplantation) is initiated for eGFR approaching 10–15 mL/min/1.73m² with uraemic symptoms. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, provides additional kidney and cardiovascular protection in diabetic kidney disease when added to standard RAAS blockade. Strict avoidance of nephrotoxins — NSAIDs, aminoglycoside antibiotics, herbal remedies, and unnecessary iodinated contrast — is essential in all patients with CKD.

Progressive CKD leads to end-stage renal disease (ESRD) requiring dialysis or kidney transplantation. Cardiovascular disease is the leading cause of death in CKD patients — risk begins from early CKD stages. Renal anemia (from erythropoietin deficiency) causes fatigue, reduced exercise tolerance, and requires erythropoiesis-stimulating agents (ESA) or IV iron therapy. Metabolic acidosis, hyperkalemia (dangerous cardiac arrhythmia risk), and renal osteodystrophy with secondary hyperparathyroidism complicate advanced CKD. Acute kidney injury (AKI) superimposed on CKD accelerates permanent loss of kidney function. Anaemia from reduced renal erythropoietin production, mineral bone disorder from impaired vitamin D activation, and secondary hyperparathyroidism all compound the cardiovascular and quality-of-life burden of elevated creatinine and progressive kidney disease.

Control diabetes and hypertension rigorously — these are the two most preventable causes of CKD globally. Avoid nephrotoxic medications: NSAIDs (ibuprofen, diclofenac) are contraindicated in CKD above stage 3; contrast agents require adequate hydration and dosing precautions; aminoglycoside antibiotics require dose adjustment and monitoring. Stay well hydrated, especially during illness and in hot weather. Never take over-the-counter pain medications long-term without medical guidance. Annual kidney function monitoring (eGFR, uACR) is recommended for all patients with diabetes, hypertension, cardiovascular disease, or family history of kidney disease.

See a GP for an incidentally elevated creatinine or eGFR below 60 on routine blood tests — this requires confirmation, investigation for underlying cause, and monitoring. Any creatinine rise of more than 25-50% above baseline over days to weeks indicates acute kidney injury (AKI) and requires urgent GP or emergency department assessment. Seek emergency care immediately for: suspected AKI (sudden reduced urine output, severe fluid retention, creatinine doubling within 48 hours); hyperkalaemia (high potassium) causing chest pain, palpitations, weakness, or ECG changes; symptoms of uraemia (confusion, vomiting, pericarditis, seizures — indicating need for urgent dialysis); or suspected urinary obstruction (anuria with flank pain — obstructed kidney requires urgent decompression). Seek nephrology referral for: eGFR below 30 (Stage 4 CKD), rapidly progressive renal impairment, proteinuria above 1g/day, suspected glomerulonephritis, or when dialysis planning is required (eGFR approaching 15).